Introduction: There is negligible evidence on the efficacy of ivermectin for treating COVID-19 pneumonia. This study aimed to assess the efficacy of ivermectin for pre-emptively treating hyperinfection syndrome in order to reduce mortality and the need for respiratory support in patients hospitalized for COVID-19.

Methods: This single-center, observational, retrospective study included patients admitted with COVID-19 pneumonia at Hospital Vega Baja from 23 February 2020 to 14 March 2021. Because strongyloidiasis is endemic to our area, medical criteria support empiric administration of a single, 200 μg/kg dose of ivermectin to prevent hyperinfection syndrome. The outcome was a composite of all-cause in-hospital mortality and the need for respiratory support.

Results: Of 1167 patients in the cohort, 96 received ivermectin. After propensity score matching, we included 192 patients. The composite outcome of in-hospital mortality or need for respiratory support occurred in 41.7% of the control group (40/96) and 34.4% (33/96) of the ivermectin group. Ivermectin was not associated with the outcome of interest (adjusted odds ratio [aOR] 0.77, 95% confidence interval [CI] 0.35, 1.69; = 0.52). The factors independently associated with this endpoint were oxygen saturation (aOR 0.78, 95% CI 0.68, 0.89, < 0.001) and C-reactive protein at admission (aOR: 1.09, 95% CI 1.03, 1.16, < 0.001).

Conclusions: In hospitalized patients with COVID-19 pneumonia, ivermectin at a single dose for pre-emptively treating is not effective in reducing mortality or the need for respiratory support measures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222278PMC
http://dx.doi.org/10.3390/v15051138DOI Listing

Publication Analysis

Top Keywords

mortality respiratory
20
respiratory support
16
covid-19 pneumonia
16
in-hospital mortality
12
ivermectin
8
retrospective study
8
efficacy ivermectin
8
pre-emptively treating
8
hyperinfection syndrome
8
mortality
5

Similar Publications

Large floods drive changes in cause-specific mortality in the United States.

Nat Med

January 2025

Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA.

Flooding greatly endangers public health and is an urgent concern as rapid population growth in flood-prone regions and more extreme weather events will increase the number of people at risk. However, an exhaustive analysis of mortality following floods has not been conducted. Here we used 35.

View Article and Find Full Text PDF

Combating COVID-19 and its co-infection by Aspergillus tamarii SP73-EGY using in vitro and in silico Studies.

Sci Rep

January 2025

Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, 33 El Buhouth St, Dokki-Giza, Egypt.

The COVID-19 pandemic has caused significant mortality and morbidity for millions of people. Severe Acute Respiratory Syndrome-2 (SARS-CoV-2) virus is capable of causing severe and fatal diseases. We evaluated the antiviral properties of Aspergillus tamarii SP73-EGY isolate extract against low pathogenic coronavirus (229E), Adeno-7- and Herpes-2 viruses.

View Article and Find Full Text PDF

Nanocarrier vaccines for respiratory infections.

Trends Mol Med

January 2025

School of Life Science, Advanced Research Institute of Multidisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, China. Electronic address:

Respiratory infections continue to pose a major global health challenge, leading to high morbidity and mortality. Effective vaccines are crucial for prevention of these, and nanotechnology offers a promising approach to enhance vaccine efficacy through nanocarrier systems. This review explores recent advances in nanocarrier-based vaccines for respiratory pathogens, focusing on their ability to promote mucosal immunity against viral infections.

View Article and Find Full Text PDF

Association of Forced Expiratory Volume in 0.5s With All-Cause Mortality Risk in Adults.

Arch Bronconeumol

December 2024

State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangzhou National Laboratory, Guangzhou, China. Electronic address:

Introduction: Previous studies have proposed forced expiratory volume in 0.5s (FEV) to determine health outcomes in infants and young children, but few studies exist in adults. This study aims to investigate the associations between FEV and all-cause mortality in adults.

View Article and Find Full Text PDF

Effect of telemedicine support for intraoperative anaesthesia care on postoperative outcomes: the TECTONICS randomised clinical trial.

Br J Anaesth

January 2025

Department of Anesthesiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; Institute for Informatics, Data Science and Biostatistics, Washington University School of Medicine in St Louis, St. Louis, MO, USA.

Background: Telemedicine may help improve care quality and patient outcomes. Telemedicine for intraoperative decision support has not been rigorously studied.

Methods: This was a single-centre randomised clinical trial of unselected adult surgical patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!